Crohn's Disease Treatment Studies

If you are looking for clinical trials for Crohn's disease you have come to the right place! As researchers, our goal is to discover new therapies and information about Inflammatory Bowel Disease (IBD), but most importantly, provide an alternate therapy that helps YOU. We welcome you to the IBD Research Team and encourage you to look at the studies below that you may qualify for. We will update this site periodically, so keep checking this page for new studies. If you have ANY questions or are interested in participating please feel free to call (734) 615-4843 or e-mail higginsSCteam@umich.edu. We hope to hear from you soon!


AMG 181

A randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and efficacy of AMG 181 in subjects with moderate to severe Crohn’s disease

Enrollment status: UPCOMING

Study Coordinator: Katy Patten

Drug: AMG 181 protein – subcutaneous injection (under the skin)

This is a phase 2 placebo-controlled, multiple dose study to evaluate the efficacy of AMG 181 compared with placebo as measured by the proportion of subjects in remission (CDAI score < 150) at week 8. AMG 181 is a fully human monoclonal immunoglobulin IgG2 antibody that specifically recognizes the human α4β7 integrin heterodimer. AMG 181 binds α4β7 with high affinity and blocks its interaction with MAdCAM-1. This mechanism of action of AMG 181 reduces pathological bowel inflammation. Subjects will be randomized in a 2:1:2:1 ratio to receive placebo or AMG 181 21 mg, 70 mg, or 210 mg. At the end of the double-blind period (week 24), subjects will enter a 108-week open-label period during which all subjects will receive open-label 210 mg AMG 181 every 3 months.


Tofacitinib for Crohn’s disease

A randomized, double-blind, placebo-controlled, parallel group, multi-centre study to investigate the safety and efficacy of CP-690,550 for induction therapy in subjects with moderate to severe Crohn’s disease

Enrollment status: UPCOMING

Study Coordinator: Kay Sauder

Drug: Tofacitinib (CP-690,550) – oral medication

This is a phase 2b study of subjects with moderately to severely active Crohn’s disease. The medicine is a JAK inhibitor made by Pfizer. JAK inhibition is a novel approach for treating a variety of autoimmune and inflammatory diseases. JAK inhibitors interrupt signaling downstream of a multiplicity of cytokines, rather than blocking one cytokine at a time, as in case of anti-TNF or interleukin-6 blockers. It is taken in pill form.

The study lasts 8 weeks and involves a screening visit, a week 0/baseline appointment, follow-up visits at week 2, week 4, and week 7 to assess response to the medicine. Finally, at week 8 we will assess the subject’s eligibility to continue in the program. Those who complete the treatment period and meet the definition of clinical response or clinical remission will be eligible to enter a placebo-controlled maintenance study of 26 weeks and then the open-label extension study, meaning there is no placebo and you are guaranteed active drug.